

Eastwood Bio-Medical Canada Inc. (EBM)

July 4, 2018

2018年7月4日



1130-4871 Shell Road, Richmond, BC, Canada V6X3Z6



Forward-Looking Statement / 前瞻性陈述

This presentation contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Eastwood Bio-Medical Canada Inc. (the Company) and the Company's affiliates, including expectations and assumptions concerning TSX Venture Exchange approvals. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.



Eastwood Bio-Medical Canada Inc. is located at Richmond, British Columbia, Canada near the Vancouver International Airport.

Eastwood Bio-Medical Canada Inc. 位于加拿大卑诗省列治文，临近温哥华国际机场。

Canadian History in Diabetes Leadership

加拿大是糖尿病行业的全球先驱

Canada has long been considered the global pioneer of diabetes industry. In 1922, Frederick Grant Banting discovered insulin, which is considered one of the most important discoveries of the 20th century. The Nobel Foundation awarded his team Nobel Prize in Physiology and Medicine in 1923.

人们长期以来一直将加拿大视为糖尿病行业的全球先驱。**1922年**，弗雷德里克·班廷(Frederick Grant Banting)发现了胰岛素，这被认为是**20世纪最重要的发现之一**。诺贝尔基金会于**1923年**授予弗雷德里克·班廷的团队诺贝尔生理学 and 医学奖。



Who We Are

关于我们

A biomedical research and development company specializing in metabolic disorders such as diabetes, obesity, hypertension, and Alzheimer's disease.

一家生物医学研发公司，致力于研究糖尿病、肥胖症、高血压和阿尔茨海默病等代谢紊乱疾病的解决方案。

We have successfully developed over 70 Eleotin® products including over 50 Health Canada (Canadian FDA) approved products.

我们已经成功开发了**70**多种Eleotin®产品，其中包括**50**多种加拿大卫生部（加拿大**FDA**）批准的产品。

Advertising Standards Canada (ASC) approved our flagship product, Eleotin® Bentley to be marketed as “World's #1 Doctor recommended Natural Source Healthy Blood Glucose Promoting Product available in Canada”.

加拿大广告标准委员会(ASC)批准本公司的旗舰产品Eleotin® Bentley用“**世界第一**医生推荐的纯天然加拿大健康血糖促进产品”名义进行市场推广。



医生推荐世界第一：3000+
 电视报纸报道范围最广：2500
 第三方临床实验世界最多：7
 各国糖尿病协会极力推荐：4
 获得各国卫生部批号世界最多：9
 有记录的产品使用者世界最多：500,000+
 实现血糖正常化的天然草本产品

世界第一医生推荐的加拿大纯天然血糖健康促进产品

这是加拿大广告标准局 (ASC) 于2014年12月15日批准使用的广告语，广告批号：DP536486-E



100%纯天然
 100%科学验证
 100%安全无副作用
 实现血糖正常化
 修复新陈代谢引发的综合症
 获加拿大及中国等先进国家卫生部许可，无需医生处方

ASC
Approval
Number

ASC
批准文号



东林公司微信公众号



东林公司微信号

Eastwood Bio-Medical Research Inc.
 Unit 1130-4871 Shell Road
 Richmond, B.C. Canada, V6X 3Z6
 Tel No.: 604.247.2100
 Toll Free No.: 1.888.669.4372
 Email: info@eastwoodcos.com

Who We Are

关于我们

Over 500,000 users are estimated to have used and benefited from Eleotin®.

估计有超过**500,000**名使用者用过**Eleotin®**并从中受益。

More than four international diabetes associations strongly recommend (endorsed) Eleotin®.

超过四个国际糖尿病协会强烈推荐（认可）**Eleotin®**。

Eleotin® was the recipient of 2010 Best Metabolism Disorder Treatment of the Year Award and

Eleotin®获得2010年度最佳新陈代谢紊乱治疗奖和

7th Annual International Brand Packing Awards

第七届年度国际品牌包装奖

EBM: The Recent Focus of Financial Analysts and Investors EBM：金融分析师和投资者近期所关注的焦点

Company production capacity ‘recently’ has increased to:

公司产能“近期”实现增长：

- Up to 3 million capsules can be produced and 10,000 bottles can be packaged per day.
每天可生产多达300万粒胶囊，每天可包装10,000瓶胶囊。
- A half million dollar worth of products in retail value can be produced daily.
每天可生产零售价价值达\$50万的产品。
- Up to \$7 million in possible savings in annual manufacturing costs.
所节约的年度制造成本高达\$700万。



EBM: The Recent Focus of Financial Analysts and Investors

EBM : 金融分析师和投资者近期所关注的焦点



EBM: The Recent Focus of Financial Analysts and Investors

EBM :
金融分析师和投资者近期所关注的焦点

New Product Approvals and Licenses (45 NPN Numbers). 新产品批号和许可证 (45 NPN批号)



June 29 2018, Eastwood Bio-Medical Canada Enters Binding Terms for Asian Exports

2018年6月29日, Eastwood Bio-medical Canada Inc.签订产品出口亚洲协议

- **On June 29 2018, EBMC announced to enter binding terms for Asian exports. Accordingly, 900% increase in revenue was announced.**

2018年6月29日, EBMC宣布与一家亚洲分销公司就采购订单达成具有约束力的条款。因此, EBMC宣布收入增加900%。

- **New manufacturing capabilities allow us to finally start producing highly advanced and complex products with the best quality and process control on a meaningfully larger scale.**


新的制造能力令我们能够大幅提高产能, 采用最佳的工艺控制技术, 开始生产非常先进、复杂的高品质产品。

- **EBMC is no longer being bound by production limitations. EBMC不再受产量限制的约束。**

Stock Prices in the Past 6 Months


过去6个月股价

The market has begun paying attention.
市场开始关注本公司。




Trading Volume in the Past 6 Months

过去6个月成交量



Market Potential: Prevalence of Diabetes By IDF Region


市场潜力：国际糖尿病联盟地区的糖尿病患病率



Market Potential: Prevalence of Alzheimer's and Dementia

市场潜力：阿尔茨海默氏症和痴呆症的患病率

全世界的阿尔茨海默氏症和痴呆症患者
Alzheimer's and dementia patients worldwide




Market Potential: Prevalence of Hypertension

市场潜力：高血压病的患病率

Global Prevalence of Hypertension
over 1.3 Billion

全球有超过**13**亿高血压病患者



Market Values of Diabetes, Hypertension and Alzheimer's 糖尿病、高血压和阿尔茨海默氏症的市场规模

- **Type 2 diabetes market to more than double, to \$64 billion by 2026**
治疗**2型**糖尿病的市场规模将增加一倍以上，到**2026**年达到**\$640亿**
- **Global hypertension market will reach USD \$32 billion by the end of 2020**
到**2020**年底，全球治疗高血压病的市场规模将达到**320**亿美元。
- **The global Alzheimer's market is expected to \$10.4 billion in 2021**
预计到**2021**年，全球治疗阿尔茨海默氏症的市场规模将达**\$104亿**

Our Claim: The Only Option

我们的主张：我们的产品是患者的唯一选择

We believe that our products are the ‘only’ option for those inflicted with these diseases.

我们相信，我们的产品是患有这些疾病的患者的“唯一”选择。

We also believe we will remain the only option in the near future.

我们也相信，在不久的将来，我们的产品仍将是患者的唯一选择。

Here is why...

理由是.....

Advantage #1: Modes of Action Known

Pharmaceutical Drugs and Insulin	Other Herbal Products	Traditional Chinese Medicine	Folkloric Treatments / Alternative Treatments	Eleotin®
Known - Can be used with other pharmaceutical drugs	Unknown	Unknown	Unknown	Known - Can be safely used with other pharmaceutical drugs

- The Modes of Actions for most non-pharmaceutical treatments are unproven. They can not be used with pharmaceutical drugs out of fear of unknown adverse interactions.
- Eleotin®'s modes of actions are known and proven. Eleotin® is safe when used with oral pharmaceutical drugs and insulin.
- In fact, Eleotin® reduces the side effects and resistance of oral pharmaceutical drugs and insulin. When used with Eleotin®, oral pharmaceutical drugs and insulin become safer more efficacious and less habit forming.

优势1：作用机制已知

药物和胰岛素	其他草药	中药	民间疗法/ 非传统疗法	Eleotin®
已知——可与其他药物一起使用	未知	未知	未知	已知——可安全地与其他药物一起使用

- 大多数非药物疗法的作用机制尚未得到证实。由于担心未知的不良相互作用，非药物疗法不能与药物一起使用。
- **Eleotin®**的作用机制众所周知。当**Eleotin®**与口服药物和胰岛素一起使用时，**Eleotin®**安全有效。
- 事实上，**Eleotin®**能减少口服药物和胰岛素的副作用和抗药性。当口服药物和胰岛素与**Eleotin®**一起使用时，能实现安全有效的疗效并减少药物依赖。

Advantage #2: Long Term Effects

优势2：长期影响

Pharmaceutical Drugs and Insulin 药物和胰岛素	Other Herbal Products 其他草药	Traditional Chinese Medicine 中药	Folkloric Treatments/ Alternative Treatments 民间疗法/非传统疗法	Eleotin®
None 无	None 无	Unknown 未知	None 无	Semi-permanent efficacy 半永久性的长期改善

- **With proven insulin resistance reduction, Eleotin® provides semi-permanent long term improvement while other treatments do not give such long term benefits.**
随着胰岛素抗病力的降低，Eleotin®可提供半永久性的长期疾病改善，而其他治疗方法则无法带来长期效益。
- **Most other treatments only have short term control benefits, and must be used permanently.**
大多数其他疗法只有在短期内控制疾病，必须永久使用这些疗法。
- **But a person can stop Eleotin® with no harmful side effects after the body has attained structural change.** 但使用Eleotin®的患者在身体实现结构变化后，可以停止使用Eleotin®并且没有任何有害副作用。

Advantage #3: Preventive Effects

优势3：预防效果

Pharmaceutical Drugs and Insulin 药物和胰岛素	Other Herbal Products 其他草药	Traditional Chinese Medicine 中药	Folkloric Treatments/ Alternative Treatments 民间疗法/ 非传统疗法	Eleotin®
No 否	No 否	No 否	No 否	Yes 是

- A person who does not have diabetes can use Eleotin® for general health and preventive purposes. Other treatments do not offer such safe options.
非糖尿病患者可以用Eleotin®改善健康状况和进行糖尿病预防。其他疗法无法提供这一安全选项。

Conclusion 结论

Pharmaceutical Drugs and Insulin 药物和胰岛素	Other Herbal Products 其他草药	Traditional Chinese Medicine 中药	Folkloric Treatments/ Alternative Treatments 民间疗法/非传统疗法	Eleotin®
Short term and invasive treatment. Toxic and severe side effects. Resistance develops. Ever increasing dosages. 短期和侵入性治疗、有毒和严重的副作用、产生抗药性、需要不断提高剂量。	Shotgun approach. Most of them rely on artificial indigestion to lower the blood sugar 突击式营销。大多依靠人为制造消化不良来降低血糖	Shotgun approach. Most of them rely on artificial indigestion to lower the blood sugar 突击式营销。大多依靠人为制造消化不良来降低血糖	Shotgun approach. Most of them rely on artificial indigestion to lower the blood sugar 突击式营销。大多依靠人为制造消化不良来降低血糖	Long term and safe beneficial effects. General health improvements. 长期安全的疗效，改善总体健康状况

- If you compare Eleotin® with other treatments from all perspectives, it's natural to conclude that Eleotin® is the only option.**

如果您从所有角度比较**Eleotin®**与其他疗法，就能自然地得出结论：**Eleotin®** 是唯一的选择。

As a Result, 因此,

ASC approved Eleotin® to be “**World’s #1** Doctor recommended Natural Source Healthy Blood Glucose Promoting Product available in Canada”.

加拿大广告标准委员会(ASC)批准Eleotin用“加拿大市场上**世界第一**医生推荐的天然来源健康血糖促进产品”名义进行市场推广。

- **World’s No.1 Doctor recommended: Over 3000+ doctors** / 全球首个医生推荐：逾**3000**名医生推荐
- **Over 2,500 Newspaper & Television Acclaims (including New York Times #1 Best Sellers)** / 得到超过**2500**条报纸和电视台赞誉（包括《纽约时报》排名第一的畅销书）
- **Researched/Clinically tested by Universities and Governments** / 由大学和政府进行研究/临床测试
- **Strongly recommended by more than 4 International Diabetes Associations** / 得到**4**个以上国际糖尿病协会的强烈推荐
- **Licenses issued by 8 Government Authorities** / 获得**8**个政府机关签发的许可证
- **Best Metabolism Disorder Treatment of the Year 2010 Award Winner** / 获得**2010**年度最佳新陈代谢紊乱治疗奖
- **More than 500,000 Users as of beginning of this year** / 截至今年年初，已有超过**500,000**名使用者
- **Over 2,000 Youtube testimonials** / 超过**2,000**个Youtube视频推荐

International Diabetes Associations Endorsements of Eleotin®

国际糖尿病协会认可Eleotin®

艾莉奥汀的主要成份是什么?

艾莉奥汀的主要成份是... (text continues with chemical and biological details)

艾莉奥汀对那些人有影响?

艾莉奥汀对那些患有... (text continues with patient information)

艾莉奥汀如何服用?

艾莉奥汀的服用方法是... (text continues with dosage instructions)

艾莉奥汀有没有副作用?

艾莉奥汀的副作用包括... (text continues with side effect information)

艾莉奥汀的安全性如何?

艾莉奥汀的安全性已经... (text continues with safety information)

糖尿病教育报

主办单位: 南京保康保健用品有限公司
 协办单位: 南京保康保健用品有限公司

你已经自由了

“艾莉奥汀”帮助糖尿病患者摆脱困境

——南京保康保健用品有限公司总经理董一勇

糖尿病患者中... (text continues with a testimonial or report)



艾莉奥汀... (text continues with product information)

艾莉奥汀... (text continues with product information)

(特刊)
 教育资料
 注意保存



새 "당뇨병치료물질" 개발

“천연약초서 추출... 부작용 전혀 없어”

EBMR 논문 공동발표

캐나다 갈가리대 외대 당뇨연구센터와 개발 파트너인 EBMR사는 천연약초에서 새로운 당뇨병 치료물질인 ‘P-700’을 개발하는 데 성공했다고 공동 발표했다. 이에 앞서 EBMR사는 이미 ‘P-700’을 이용한 건강차 ‘엘리오틴’을 지난 4월부터 북미지역에서 판매하기 시작했으며, 당뇨병 치료용 개발을 추천중이다.

공동개발자인 EBMR사는 캐나다 밴쿠버 소재의 의료기업인 이스트우드사(결핵성 식물의 자엽사)로 당뇨병과 암치료제를 전문적으로 개발중인 신약개발 전문회사이다.

‘P-700’으로 명명된 이 당뇨병 치료물질은 천연약초에서 추출된 기존 당뇨병 치료제에 비해 부작용이나 내성이 전혀 없는 것으로 나타났다고 갈가리대 학과 EBMR사는 밝혔다. EBMR사는 “임상실험 결과 ‘P-700’은 혈당을 조절하는 기존 당뇨병치료제에 기능외에도 인슐린을 생산하는 세포의 배양세포 기능을 강화하고, 근육 조직에서 인슐린을 잡아내는 수송체를 생성하는 효능까지 있다”고 밝혔다.

EBMR사는 “성인병의 대명사로 한자병으로 알려진 당뇨병을 치료할 수 있는 길을 보여준 셈”이라고 설명했다. 하지만 이런 신약이 개발돼 당뇨병자에게 보급되기까지 걸리는 기간은 대략 7-10년이 걸린다고 한다.

약사공론 1988. 10. 8. 제 3081 호

당뇨치료제 개발 캐나다 윤치원박사

캐나다 연구하는 고도혈당... 신약이 개발에 들어가 되고... (text continues with news snippet)

이런 장수관련 신약은... (text continues with news snippet)

공동개발자인 EBMR사는... (text continues with news snippet)

‘P-700’으로 명명된 이... (text continues with news snippet)

EBMR사는 “성인병의... (text continues with news snippet)

Recommendations of Medical Professionals



Dr. Chu, Beijing China
“Because of Eleotin my husband doesn’t need any pharmaceutical drugs. He’s normal now.”



Dr. J. Yoon
“This remedy will restore near normalcy for 70% of Type II diabetics.”



Dr. L. Lipskaya, Bacteriologist
“After I started using Eleotin, I felt an improvement in my health conditions. Now I recommend Eleotin to every person who are suffering from Type II diabetes.”



Dr. M. Sichel
“A pathfinding discovery in the reversal of diabetes.”



Dr. P. Singh
Ayurvedic Medicine
“I want to recommend Eleotin especially to Type II diabetics. It will help them in controlling their blood glucose levels.”



Dr. C. L. Broadhurst
“Eleotin is blend of many promising herbs that dramatically lower blood sugar.”



Dr. M. Kuypers
“I am using it myself, with great benefit. My own experience have been most encouraging. I am looking forward to finally being able to do something about insulin resistance.”



Dr. E. Echano
“Everyone should know about this. i observed excellent clinical result. This unique herbal formulations long lasting effects are truly amazing.”



Dr. D. Walker
“Eleotin is effective in regulating blood glucose levels.”

Recommendations of Medical Professionals

医疗专业人员推荐



Chu博士，中国北京

“因为**Eleotin**，我的丈夫不需要任何药物。他现在过着正常健康的生活。”



J. Yoon博士

“对于**70%**的**2型**糖尿病患者，这种药物将使患者恢复到接近健康正常的状态。”



L. Lipskaya博士，细菌学家

“在我开始使用**Eleotin**之后，我感觉自己的健康状况有所改善。现在我向所有患有**II型**糖尿病的人推荐**Eleotin**。”



M. Sichel博士

“**Eleotin**是逆转糖尿病的突破性发现。”



P. Singh博士

阿育吠陀医学

“我想特别向**II型**糖尿病患者推荐**Eleotin**。它将帮助患者控制血糖水平。”



C. L. Broadhurst博士

“**Eleotin**由许多草药混合而成，可以显著降低血糖。”



M. Kuypers博士

“我自己使用它，它给我带来了很大的好处。我自己的经历是最令人鼓舞的。我期待着能够对胰岛素抗药性做些什么。”



E. Echano博士

“每个人都应该知道这一点。我观察到**Eleotin**有极好的临床效果。这种独特的草药配方有持久疗效，确实令人惊叹。”



D. Walker博士

“**Eleotin**可有效调节血糖水平。”

Clinical Studies, Publications, Approvals and Licenses

临床研究、出版物、批文和许可证



Section and Family Safety Agency of the Center for Disease Prevention and Control, People's Republic of China

Testing Report

Manufacturer/Supplier:	Eleotin
Name of Sample:	Eleotin
Sample received from:	Eleotin International Enterprise Co., Ltd Toronto, Ont. Free Trade Zone
Manufacturer:	Eleotin International Enterprise Co., Ltd
Sample No. (Lot):	20040204
Expiration Date:	18 months from manufacturing date (expiration date after next test completion)
Sample Description:	Type: capsule Color: white, round, light brown powder
Amount of Sample Received:	6.1g (approx. 30 capsules) in 1 bottle + 200g
Sample Received on:	May 12, 2004
Testing Criteria:	Sample 1: Eleotin as a supplement in accordance with general food safety management
Testing Scheme:	Eleotin Health Products Testing and Evaluation Guidelines, 2002

Testing Results

The results show that Eleotin had no effect on the blood glucose levels of the normal subjects (reference group) after fasting (0-8h). Compared with the glucose standard control group, Eleotin effectively lowered the blood glucose levels (p<0.05) in the 2-4h of energy discharge state with progressively high blood glucose levels induced by Nilsson in all Eleotin dose groups (High dose, middle dose and low dose). After oral loading of glucose in all Eleotin dose groups, the blood glucose levels of these groups were not lower than that of the glucose standard control group (0-4h). According to the standards set by National Health Products Testing and Evaluation Guidelines (2002), the testing of whether Eleotin is effective in suppressing the increase of blood glucose level in an animal experiment showed positive results. Level of proof:



卫生部认定保健食品检验机构
卫生部卫监发(1996年)第53号

University of Calgary (UTI) officials



Press conference at the launching of the first Eleotin

Clinical Studies, Publications, Approvals and Licenses

临床研究、出版物、批文和许可证

精品汇 指南

成功就是这样简单

——300例糖尿病患者服用博特力效果分析

博特力胶囊在北美上市已有八年，数以万计的糖尿病患者摆脱了困苦。自去年在国内上市以来，已被越来越多的国内糖尿病患者所认可，尤其在调节血糖、预防和改善糖尿病并发症方面，博特力胶囊更显示出它独特的功效。

为了让更多的糖尿病患者了解服用博特力的效果，我们随机抽调了300例正在服用该产品的患者，并做了比较详细的回访分析。

在抽取的300例顾客中，各年龄阶段的人群都有，年龄最小的23岁，最大的87岁；他们服用博特力的时间长短各异，最短的服用一个月，最长的服用八个月；其中明确诊断为II型糖尿病的256人，糖耐量异常的44人。

在确诊为II型糖尿病的256个顾客中，患病时间、血糖控制情况及并发症、合并症各有不同。有的患者是刚刚被确诊为糖尿病，有的则已确诊多年或数十年；有的患者空腹血糖高，有的只是餐后两小时血糖高，还有二者都高者；从服药情况看，有单纯口服用药，有单纯注射胰岛素，也有联合应用者。发病五年以上的患者基本都合并一至多种并发症、合并症，且临床表现症状各异，如手脚麻木疼痛，乏力，失眠，皮肤瘙痒，视力下降等等。

上述顾客在服用博特力胶囊后，70%以上的血糖逐渐平稳，98%并发症有了明显的改

善，有部分顾客已减少降血糖药物的用量，现做如下表格以帮助分析：

一、服用博特力时间，减、停用降血糖药物人数和百分比

服用时间	人数(个)	减、停药人数	百分比
6个月以上	96	62	64.6%
4~6月	142	59	41.5%
2~3月	40	5	12.5%
1个月	22		

二、服用博特力前后的血糖及症状比较表

服前的血糖及症状	人数(个)	服后血糖或症状改善人数(个)	有效率
血糖偏高	224	187	83.5%
血糖控制良好	32	32	100%
糖耐量异常	44	39	86.6%
手脚麻木	56	47	83.9%
乏力、易疲劳	65	48	73.8%
皮肤瘙痒	30	22	73%
睡眠欠佳	34	25	73.5%
视力下降	38	16	42.1%
出汗多	26	15	57.7%
口干	43	28	65.1%
夜尿频	49	27	55.1%
足部红肿	3	2	66.7%
阳痿	7	6	85.7%

以上是300例服用博特力顾客的情况分析，通过上述数据我们欣喜地看到博特力胶囊的特殊作用。如果给博特力胶囊充足的时间去滋养和调理身体，就会显示出它独特而强大的效果。即使停用降血糖药物和博特力胶囊，仍能保持70%以上的糖尿病患者的血糖维持在正常水平或近乎正常的水平，不会出现反弹。

博特力胶囊之所以有如此强大的效果，是因为博特力胶囊能激发和恢复胰腺的基本功能，促进β细胞的再生和修复，增加胰岛素的分泌；同时还具有恢复胰岛素与受体细胞之间结合力作用，减少胰岛素抵抗，提高胰岛素受体和胰岛素的结合率，大大提高了对人体释放胰岛素的利用率，从而充分进行葡萄糖代谢，使机体获得自身调节血糖的能力。

Clinical Studies, Publications, Approvals and Licenses

临床研究、出版物、批文和许可证

약업신문 1998년 10월 8일 목요일 Executive

캐나다에 거주하는 교포의학자가 참여하고 교포가 운영하는 회사들이 공동으로 획기적인 당뇨병 치료제를 개발한 것으로 알려져 주목되고 있다.

최근 캐나다의 한 교포회사인 EBMR(Eastwood Bio-Medical Research Inc.)사가 발표한 바에 따르면 이번에 개발된 약물

은 700여 차례의 임상실험을 실시한 결과 발병 6개월 이내의 성인형 당뇨병을 70% 이상 치료한 것으로 밝혀졌다.

P-700이라는 이 약물은 전 각종 천연약초에서 추출된 생약물질로 되어 있어 부작용과 내성이 전혀 없다고 EBMR 측은 발표했다.

EBMR은 이 약물이 혈당조절뿐 아니라 인슐린을 생산하는 췌장 베타세포의 기능을 강화하고 근육조직에서 인슐린을 잡아치는 수용체를 다시 살아나게 해 당뇨병을 근본적으로 치료해 준다고 설명했다.

이번 당뇨병 치료제는 캐나다 칼거리대학교 당뇨병연구센터가 기초연구 및 동물실험등을 실시했고 제공하는 EBMR측에서 추진하고 있는 것으로 전

ty Technologies International이라는 회사를 통해 EBMR과 상품개발 계약이 체결됐다.

이번 신약개발에 일조한 윤박사는 23년간 바이러스와 관련된 당뇨병의 원인과 예방에 대한 연구로 매우 높은 평가를 받고 있는 것으로 전해졌다.

EBMR측은 "윤박사가 노벨 의학상에 두 번이나 후보 추천된 인물일 정도로 당뇨병 분야의 세계적인 위자"라고 소개했다.


한편 EBMR사는 로열, 텔레 커뮤니케이션 장비제조, 금융투자, 국제무역등의 관련업무를 하고 있는 이스트우드(Eastwood)의 계열사이며, 의학 관련 벤처기업으로 캐나다에 거주하는 한국인 교포 김영수(42)씨가 운영하는 회사이다.

(민경두기자)

교포 획기적 당뇨병 치료제 개발
윤지원박사, 700여차례 임상 80% 완치

Comments on Eleotin by Korean National Diabetes Association 韩国国家糖尿病协会对Eleotin的评论

Clinical Studies, Publications, Approvals and Licenses 临床研究、出版物、批文和许可证



새 "당뇨병치료물질" 개발

"천연약초서 추출...부작용 전혀 없어"
EBMR한들 공동발표

캐나다 알가리대 외대 당뇨연구센터와 개발 파트너인 EBMR사는 천연약초에서 새로운 당뇨병 치료물질 개발하는 데 성공했다고 공동 발표했다.

이에 앞서 EBMR사는 이미 'P-700'을 이용한 건강차 '엘레오틴'을 지난 1월부터 북미지역에서 판매하기 시작했으며, 당뇨병치료 의약품 개발을 추진중이다.

공동개발자인 EBMR사는 캐나다 밴쿠버 소재의 프로그어업인 이스트우드서걸링주식합의 제일사로 당뇨병과 임치료제를 전문적으로 개발중인 신약개발 전문회사다.

'P-700'으로 명명된 이 당뇨병 치료물질은 천연약초에서 추출돼 기존 당뇨병 치료제에 비해 부작용이나 내성이 전혀 없는 것으로 나타났다고 알가리대학과 EBMR사는 밝혔다.

EBMR사는 "민상실험 결과 'P-700'은 혈당을 조절하는 기존 당뇨병치료제 기능외에도 인슐린을 생산하는 췌장의 베타세포 기능을 강화하고, 근육 조직에서 인슐린을 잡아내는 수용체를 재생하는 효능까지 있다"고 밝혔다.

EBMR사는 "성인병의 대명사로 난치병으로 알려진 당뇨병을 치료할 수 있는 길을 보여준 셈"이라고 설명했다. 하지만 이런 신약이 개발돼 당뇨병자에게 보급되기까지 걸리는 기간은 대략 7~10년이 걸린다고 한다.

약사공론 1998. 10. 8. 제 3081호

당뇨치료제 개발 캐나다 음지원박사

캐나다에 거주하는 고교과학자이던 당뇨 치료제 연구자인 신약이 개발돼 특허가 되고 있다.

캐나다 앨버타 대학의 음지원박사에 따르면 알가리대학교 당뇨연구센터 음지원 박사가 개발한 'P-700'이라는 천연 약제 700여 가지의 원상실험을 통해 알칼리 지 3개를 제외한 천연의 성분으로 약제사는 10종 이상을 대상으로 동물 실험을 수행할 정도로 획기적인 효과를 가지고 있는 것으로 나타났다.

이런 당뇨병 관련 신약은 영주 박사와 EBMR사와 관계있는 한 음노연구센터가 신약연구를 위한 공동연구를 추진한 결과로 신약의 상용화에 대한 권리는 EBMR사가 갖게는 제정됨으로써 이다. 엘레오틴이라는 이름의 신약치료제로 활용되어 제미지원에 관계가 인정되고 있는 것으로 확인되었다. 음지원박사는 지난 17년간 바이엘사와 공동발 당뇨병과 관련된 의학에 대한 연구로 여러 세계 일류지로 알려진 인종로 지난 KBS생물정보통신 학술부품상을 수상한 바 있다.

Comments on Eleotin by Korean Pharmaceutical Manufacturers' Association 韩国药品制造商协会对 Eleotin的评论

Africa's Best Diabetic & Hypertension Management Drug in 2010

2010年非洲最佳糖尿病和高血压管理药物



INSTITUTE FOR GOVERNMENT RESEARCH & LEADERSHIP TECHNOLOGY
Office of the Country Director/CEO (Africa & Middle East)

The Managing Director/CEO
 Eleotin GP Ltd
 Goodnews Plaza, Suite A6
 4B, Agbaku Street, Opebi, Ikeja
 Lagos State, South West Nigeria

Monday October 4 2010

Dear Sir,

**BEST DIABETIC & HYPERTENSION
 MANAGEMENT DRUG OF THE YEAR 2010**

In the spirit of Nigeria's 50th Independence celebration, Institute for Government Research & Leadership Technology have the honour to make this award in favour of **ELEOTIN GP LTD** having out performed other companies in the production of fine Diabetic pharmaceuticals in Nigeria.

- 2) Some of the parameters and performance indices used are:
- Your compliance with government regulatory laws and guidelines;
 - your prowess and contribution in the production of drugs;
 - product's high quality and value creation;
 - Corporate Marketing strategy;
 - Product's price and pricing strategy;
 - Product's acceptability, satisfaction and endorsement;
 - corporate general performance and track record;
 - product's unique selling points and competitive edge;
 - customer's continued patronage and or referrals;

2nd floor, Oakland Centre, Australian Embassy Building, Plot 2966, Agosin Street -
 Federal Capital Territory Maitama District, Abuja, Nigeria.
 TEL: + 234 - 09 - 4602947/01 - 7306559, CELL: + 234 - 08030848907/0805707980 FAX: 09 - 4613117
 Web site: <http://www.instituteforgovernmentresearch.com>, e-mail: instituteforgovernmentresearch@igrtail.com


COUNCIL

Prof. Kper Ejorl CFR Professor of Political Science/Public Administration, Chairman Prof. Ben Webozua CON, SAN Past Minister of Education
 Chief (Mrs) Precilla Kuye FOM Past President Nigerian Bar Association Prof. Mahmood Marekoti Professor of Government
 Prof. Tony Ifeanyi Professor of Government Prof. David Geden Professor of Public Leadership
 Dr. Ikeangbo Chimezie Associate Professor of Political Science & Administrative Studies
 Moses Ekele Country Director/CEO (Africa & Middle East)



Testimonials

用戶反饋



We have over 5,000 video testimonials on Youtube by users and doctors with all real names and many contact information to verify.

我们在**Youtube**上有超过**5,000**个使用者和医生的推荐视频，使用者和医生提供真实姓名和许多联系信息，以验证真实性。

Established Retail Lines

成熟的产品线



Eleotin® Bentley

- Helps promote healthy glucose levels.
有助于促进达到健康血糖水平
- Long-term blood glucose normalization effects.
达到长期实现正常血糖的效果
- General health improvement.
提升总体健康状况



Eleotin® Ma5

- Powerful anti-oxidation powers that are preserved superbly.
强大的抗氧化能力，保存完好
- High quality Vitamin C group ingredients.
含高品质的维生素C组成份

Established Retail Lines

成熟的产品线



Eleotin® LBM

- for hyperactivity of the liver (high blood pressure).
用于肝过度活跃（高血压）
- To cut the vicious cycle between high blood sugar and high blood pressure caused by prescription drugs.
减少处方药引起的高血糖和高血压之间的恶性循环



Eleotin® Pedo-Protection Socks

Eleotin® 保护袜

- Anti-Fungal & Anti-Bacterial
抗真菌和抗菌
- Auto Regulating Mesh Top
自动调节顶部网状设计
- Treated Inner Toe Seam
脚趾缝舒适
- Holistic & Gentle Neck Pressure
舒缓脚脖压力

Founder - Dr. Youngsoo Kim

创始人 - 金荣洙博士



- Advises Various Governments and senior management of numerous Korean firms including Hyundai, Gold Star, and Samsung
为各个政府、包括现代、金星和三星在内的众多韩国企业的高级管理人员提供建议
- CEO of Mutsumi Enterprises Canada Corp.
Mutsumi Enterprises Canada Corp. 首席执行官
- Vice President of Toshin Butsuruyu (Toyota Automobile Group Japan)
东新物流株式会社（丰田（日本）汽车集团）副总裁
- Protocol secretary in the Korean Presidential Palace
韩国总统府礼宾司秘书
- Assistant Professor of Finance at the University of Alberta in Edmonton
埃德蒙顿阿尔伯塔大学金融学助理教授
- Massachusetts Institute of Technology (Ph.D. in Economics) 1987
1987年毕业于麻省理工学院（经济学博士）

Board of Directors

董事会成员

Yunji Kim
President, CEO and Director
总裁、首席执行官兼董事

- President since April 2013, Director since October 2012
2013年4月起担任总裁；
2012年10月起担任董事
- New York State Bar admission 2012
2012年加入纽约州律师协会
- LL.M. in Taxation, Georgetown University Law Center, 2011
2011年获得了乔治敦大学法学院法学硕士学位

Peter Chen
CFO and Director
首席财务官兼董事

- Executive Director of Proterra Management Group Inc.
目前在私营咨询公司Proterra Management Group Inc.担任执行董事。

Dr. Terrance Owen
Terrance Owen博士
Director
董事

- Director of Pacific Paradyne Energy Inc.
目前担任Pacific Paradyne Energy Inc.董事
- CEO of CellMedX Corp.
担任CellMedx Corp.首席执行官
- President and CEO of Nuva Pharmaceuticals Inc. until June 2013
2013年6月前曾担任Nuva Pharmaceuticals Inc.的总裁兼首席执行官。

Dr. Marcus Kuypers
Marcus Kuypers博士
Director
董事

- Medical Doctor
医学博士
- Physician at AB Staffing since November 2011
自2011年11月至今一直是AB Staffing的在职医生
- Accretive Health from October 2011 to February 2013
2011年10月至2013年2月任职于Accretive Health
- Doctors Home Visits from September 2001 to August 2011
2001年9月至2011年8月在Doctors Home Visits供职
- Emergency Medicine physician since November 2011
自2011年11月至今，一直担任急救医生。

Appendix - Financial Information

附录——财务信息

Most updated information available upon request

请在网站上申请获取公司最新信息

www.eleotin.ca

www.eleotin.cn



TSX-V: EBM

Yunji Kim

Unit 1130-4871 Shell Road Richmond, B.C. Canada, V6X 3Z6

604.247.2100 or 1.888.669.4372

yunjikim@eastwoodcos.com

www.eleotin.ca

www.eleotin.cn